Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1 | MicrobiomeTrials← Back to trialsNCT06373263
Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1
CompletedNAINTERVENTIONAL
Trial Details
Start: 2025-12-05Est. Completion: 2025-12-19
Enrollment target: 511 participants Locations- Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Systemic SclerosisScleroderma
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus place…
Scottsdale, United StatesEst. completion Jan 6, 2027
Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
This study will examine families in which one sibling of a sibling pair, or twin pair, has developed a systemic rheumati…
Bethesda, United States